Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics

Area of Science:

• Oncolytic virotherapy
• Cancer gene therapy
• Viral vector development

Background:

• Human adenoviruses (HAdVs) show renewed promise for cancer treatment, with recent approvals and late-stage clinical trials.
• Therapeutic oncolytic HAdVs (oHAdVs) are engineered for cancer cell selectivity and include immunotherapeutic transgenes to enhance efficacy.
• Modifications in oHAdVs and their complex host interactions complicate pre-clinical model development.

Purpose of the Study:

• To review experimental options for pre-clinical evaluation of therapeutic oHAdV-based vectors for cancer therapy.
• To focus on Ad serotype 5 (Ad5) as the most common vector serotype.
• To address challenges in developing relevant animal models for oHAdV pre-clinical development.

Main Methods:

• Review of existing literature and pre-clinical models for oncolytic HAdV evaluation.
• Focus on modifications enhancing cancer selectivity and immunotherapeutic transgene delivery.
• Examination of challenges in assessing toxicity, immunity, efficacy, and pharmacodynamics.

Main Results:

• Adstiladrin approval and positive Phase 3 data highlight the clinical potential of oHAdVs.
• Engineered oHAdVs with transgenes show potential to overcome limitations of non-modified viruses.
• Developing accurate animal models remains a critical hurdle for oHAdV pre-clinical studies.

Conclusions:

• Pre-clinical evaluation of therapeutic oHAdVs requires careful consideration of model systems.
• Ad5-based vectors are prominent in oHAdV cancer therapy development.
• Further research into robust animal models is essential for advancing oHAdV cancer therapies.